Group 1 - iTeos Therapeutics, Inc. (ITOS) shares have increased by 31.6% over the past four weeks, closing at $7.50, with a mean price target of $23.33 indicating a potential upside of 211.1% [1] - The average price targets from analysts range from a low of $15 to a high of $47, with a standard deviation of $12.21, suggesting a high degree of variability in estimates [2] - Analysts show strong agreement on ITOS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - Recent revisions in earnings estimates for ITOS have shown two estimates moving higher and one lower, resulting in a 9.4% increase in the Zacks Consensus Estimate [12] - ITOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Group 1 - Trupanion (TRUP) closed at $36.44, with a 4.1% gain over the past four weeks, and a mean price target of $54.75 indicating a 50.3% upside potential [1] - The average price targets range from a low of $41 to a high of $65, with a standard deviation of $10.66, suggesting a variability in analyst estimates [2] - Analysts show strong agreement on Trupanion's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for Trupanion's current year earnings has increased by 64.3%, with two estimates moving higher and no negative revisions [12] - Trupanion holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]

Core Viewpoint - Under Armour (UAA) shows potential for significant upside, with a mean price target of $8.47 indicating a 46% increase from the current price of $5.80 [1] Price Targets and Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $2.97, indicating variability among analysts [2] - The lowest estimate is $4, suggesting a 31% decline, while the highest estimate predicts a surge of 158.6% to $15 [2] - Analysts' price targets are often questioned for their reliability, as they may mislead investors rather than provide accurate guidance [3][7] Earnings Estimates - Analysts are optimistic about UAA's earnings, with a consensus indicating better-than-previously estimated earnings [4] - A positive trend in earnings estimate revisions has historically correlated with stock price movements, suggesting potential upside [11] - Over the last 30 days, one estimate has increased, leading to a 0.4% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - UAA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of UAA's potential gains, it does provide a directional guide for price movement [13]

Shares of Celestica (CLS) have gained 28.9% over the past four weeks to close the last trading session at $89.21, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $120 indicates a potential upside of 34.5%.The average comprises 10 short-term price targets ranging from a low of $95 to a high of $150, with a standard deviation of $13.85. While the lowest estimate indicates an incre ...

Rambus (RMBS) closed the last trading session at $48.88, gaining 5.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.25 indicates a 47.8% upside potential.The average comprises eight short-term price targets ranging from a low of $55 to a high of $90, with a standard deviation of $9.97. While the lowest estimate indicates an increase of 12.5% from the current price level, the ...

In its upcoming report, Atmos Energy (ATO) is predicted by Wall Street analysts to post quarterly earnings of $2.92 per share, reflecting an increase of 2.5% compared to the same period last year. Revenues are forecasted to be $1.88 billion, representing a year-over-year increase of 14.4%.The consensus EPS estimate for the quarter has been revised 2.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Core Viewpoint - CDW is expected to report quarterly earnings of $1.96 per share, reflecting a 2.1% increase year-over-year, with revenues projected at $4.89 billion, a 0.4% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 2.8%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Public- Government' revenues to be $497.84 million, representing an 8.4% decrease year-over-year [4]. - 'Net sales- Public' are projected at $1.73 billion, indicating a 0.3% increase from the previous year [5]. - 'Public- Healthcare' is expected to reach $630.71 million, reflecting a 7.9% increase year-over-year [5]. - 'Net sales- Small Business' are estimated at $380.47 million, showing a slight decrease of 0.1% from the prior year [5]. - 'Public- Education' is projected at $601.26 million, a 0.8% increase from the previous year [6]. - 'Net sales- Corporate' are expected to be $2.16 billion, indicating a 0.9% increase year-over-year [6]. - 'Net sales- Other' are projected at $637.67 million, reflecting a 1% increase from the prior year [6]. Major Product and Services Estimates - 'Net sales- Major Product and Services- Other' are expected to be $25.82 million, indicating a 2.2% decrease year-over-year [7]. - 'Net sales- Major Product and Services- Hardware- Notebooks/Mobile Devices' are projected at $1.18 billion, reflecting a 3.5% increase [7]. - 'Net sales- Major Product and Services- Hardware- Netcomm Products' are estimated at $587.46 million, indicating a 3.1% increase [8]. - 'Net sales- Major Product and Services- Hardware- Desktops' are expected to reach $260.28 million, reflecting a 0.7% increase [8]. - Overall, 'Net sales- Major Product and Services- Hardware' are projected at $3.54 billion, indicating a slight decrease of 0.1% year-over-year [9]. Stock Performance - CDW shares have increased by 7.2% over the past month, contrasting with a 0.5% decline in the Zacks S&P 500 composite [9].

Core Viewpoint - Emerson Electric (EMR) is expected to report quarterly earnings of $1.42 per share, reflecting a 4.4% increase year-over-year, with revenues projected at $4.38 billion, a slight increase of 0.1% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts forecast 'Net Sales- Intelligent Devices- Total' at $3.06 billion, indicating a year-over-year change of -0.1% [5]. - 'Net Sales- Software And Control- Total' is expected to reach $1.35 billion, reflecting a 1% increase from the prior-year quarter [5]. - 'Net Sales- Intelligent Devices- Discrete Automation' is projected at $610.20 million, showing a decline of 3.5% from the year-ago quarter [5]. - 'Net Sales- Intelligent Devices- Safety & Productivity' is estimated at $355.61 million, down 2.6% year-over-year [6]. - 'Net Sales- Software and Control- Test & Measurement' is expected to be $355.83 million, indicating a 3% decrease from the prior-year quarter [6]. - 'Net Sales- Intelligent Devices- Final Control' is projected to reach $1.07 billion, reflecting a 1.8% increase from the prior-year quarter [7]. - 'Net Sales- Software and Control- Control Systems & Software' is expected at $696.17 million, indicating a 1.3% year-over-year change [7]. - 'Net Sales- Software and Control- AspenTech' is projected at $293.30 million, reflecting a 5.5% increase year-over-year [8]. - 'Net Sales- Intelligent Devices- Measurement & Analytical' is expected to be $1.02 billion, indicating a 0.7% increase from the prior-year quarter [8]. Stock Performance - Over the past month, Emerson Electric shares have recorded a return of +3.9%, contrasting with the Zacks S&P 500 composite's -0.5% change [8]. - Based on its Zacks Rank 3 (Hold), EMR is expected to perform in line with the overall market in the upcoming period [8].

Block (XYZ) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -36.36%. A quarter ago, it was expected that this mobile payments services provider would post earnings of $0.83 per share when it actually produced earnings of $0.71, delivering a surprise of -14.46%.Over the last four quart ...

Company Performance - iRhythm Technologies reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.89, but an improvement from a loss of $1.47 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $158.68 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.34% and showing an increase from $131.93 million in the same quarter last year [2] - Over the last four quarters, iRhythm Technologies has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - iRhythm Technologies shares have increased by approximately 18.5% since the beginning of the year, contrasting with a decline of 5.3% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.55 on revenues of $171.04 million, and for the current fiscal year, it is -$1.75 on revenues of $681.28 million [7] Industry Outlook - The Medical Info Systems industry, to which iRhythm Technologies belongs, is currently ranked in the top 18% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of iRhythm Technologies' stock may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]